Source: BioSpace

Resolution Bioscience Inc: Resolution Bioscience (a part of Agilent) Investigated Acquired Resistance to KRAS G12C Inhibition

Agilent Technologies Inc. (NYSE: A) today announced the publication of a study carried out in partnership with Resolution Bioscience (a part of Agilent) and Dana-Farber Cancer Institute .

Read full article »
Resolution Bioscience Inc's Competitors | Resolution Bioscience Inc's News | Resolution Bioscience Inc's Financials
Stay up-to-date with the latest news on Resolution Bioscience
Est. Annual Revenue
$25-100M
Est. Employees
25-100
Mark Li's photo - President & CEO of Resolution Bioscience

President & CEO

Mark Li

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Resolution Bioscience